Summary of Study ST002349

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001509. The data can be accessed directly via it's Project DOI: 10.21228/M8N71K This work is supported by NIH grant, U2C- DK119886. See: https://www.metabolomicsworkbench.org/about/howtocite.php

Study ID	ST002349
Study Title	Biomolecular condensates create phospholipid-enriched microenvironments (Part 1)
Study Type	Metabolomes of in vitro synthesized condensates
Study Summary	Proteins and RNA are able to phase separate from the aqueous cellular environment to form sub-cellular compartments called condensates. This process results in a protein-RNA mixture that is chemically distinct from the surrounding aqueous phase. Here we use mass spectrometry to characterize the metabolomes of condensates. To test this, we prepared mixtures of phase-separated proteins and cellular metabolites and identified metabolites enriched in the condensate phase. These proteins included SARS-CoV-2 nucleocapsid, as well as low complexity domains of MED1 and HNRNPA1.
Institute	Cornell University
Department	Department of Pharmacology
Laboratory	Dr. Samie Jaffrey
Last Name	Dumelie
First Name	Jason
Address	1300 York Ave, LC-524, New York City, NY
Email	jdumes98@gmail.com
Phone	6465690174
Submit Date	2022-11-04
Raw Data Available	Yes
Raw Data File Type(s)	mzdata.xml
Analysis Type Detail	LC-MS
Release Date	2023-03-01
Release Version	2

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR002603
Treatment Summary:	Mouse liver metabolites were combined with either the condensate-forming low-complexity domains of HNRNPA1, MED1 or full-length SARS-CoV-2 nucleocapsid. Condensates were stimulated with either 0 nM, 150 nM or 600 nM RNA. Condensates were centrifuged to the bottom of a 600 ul tube. Equal fractions from the input sample, aqueous phase and condensate phases were collected separately. Metabolites were extracted from each fraction.

Treatment ID:

TR002603

Treatment Summary:

Mouse liver metabolites were combined with either the condensate-forming low-complexity domains of HNRNPA1, MED1 or full-length SARS-CoV-2 nucleocapsid. Condensates were stimulated with either 0 nM, 150 nM or 600 nM RNA. Condensates were centrifuged to the bottom of a 600 ul tube. Equal fractions from the input sample, aqueous phase and condensate phases were collected separately. Metabolites were extracted from each fraction.